<DOC>
	<DOC>NCT00440297</DOC>
	<brief_summary>To describe the immunogenicity and safety of modified process hepatitis B vaccine administered to renal predialysis and dialysis patients</brief_summary>
	<brief_title>Hepatitis B Vaccine Predialysis/Dialysis Study (V232-060)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male and female subjects at least 18 years of age Laboratory confirmed negative serology result to HbsAg (hepatitis b virus), antiHBs (antibody to hepatitis B surface antigen), and anti HBc (antibody to hepatitis B core antigen) within 6 weeks of the initial dose of study vaccine Patient on renal dialysis or a predialysis patient with a creatinine clearance of &lt;=30 ml/min Previous hepatitis B infection, vaccination with any hepatitis B vaccine Recent febrile illness; hypersensitivity to any component of licensed hepatitis B vaccines Recent administration of immune globulin, licensed inactivated vaccine within 14 days or licensed live vaccine within 30 days prior to receipt of first study vaccine Receipt of investigational drugs or investigational vaccines within 3 months prior Impairment of immunologic function Recent use of systemic immunomodulatory medications Pregnant women, nursing mothers or women planning to become pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>hepatitis B virus</keyword>
</DOC>